Shi Vivian Y, Güler Erman, Esparza Brian, Silverberg Jonathan I
University of Washington Medicine, Seattle, WA, USA.
Pfizer Inc., Istanbul, Turkey.
Dermatol Ther (Heidelb). 2025 Aug 6. doi: 10.1007/s13555-025-01491-2.
As the number of systemic agents available for the treatment of moderate-to-severe atopic dermatitis (AD) continues to increase, it is likely that patients may need or want to switch from one treatment to another. Owing to differences in the mechanism of action, the systemic agents abrocitinib (an oral Janus kinase 1-selective inhibitor) and dupilumab (an injectable interleukin 4 alpha antagonist) are associated with distinct efficacy and safety profiles. Two recent publications have examined the efficacy and safety of long-term abrocitinib in patients previously treated with dupilumab. In this podcast article, two dermatologists discuss the management of moderate-to-severe AD and highlight factors to consider before changing therapies in the context of these recent studies, focusing on switching from dupilumab to abrocitinib treatment.Below is the link to the electronic supplementary material. Supplementary file1 (MP4 173881 KB).
随着可用于治疗中重度特应性皮炎（AD）的全身性药物数量持续增加，患者可能需要或想要从一种治疗方法转换至另一种治疗方法。由于作用机制不同，全身性药物阿布昔替尼（一种口服的Janus激酶1选择性抑制剂）和度普利尤单抗（一种注射用白细胞介素4α拮抗剂）具有不同的疗效和安全性特征。最近有两篇出版物研究了长期使用阿布昔替尼对先前接受过度普利尤单抗治疗的患者的疗效和安全性。在这篇播客文章中，两位皮肤科医生讨论了中重度AD的管理，并强调在这些最新研究的背景下更换治疗方法之前需要考虑的因素，重点是从度普利尤单抗转换为阿布昔替尼治疗。以下是电子补充材料的链接。补充文件1（MP4，173881KB）。
